scholarly journals Analysis of Soluble Mesenchymal-Epithelial Transition Factor and Hepatocyte Growth Factor Serum Levels in Children With Autism Spectrum Disorder

2022 ◽  
Vol 8 (1) ◽  
pp. 26-32
Author(s):  
Somayeh Shabani ◽  
◽  
Soheila Talesh Sasani ◽  
Farhad Mashayekhi ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Autism Spectrum ◽  
Vital Role ◽  
Serum Concentrations ◽  
Neurology Clinic ◽  
The Mean ◽  
Mesenchymal Epithelial Transition Factor ◽  
Hepatocyte Growth

Background: Hepatocyte Growth Factor (HGF) and its receptor, Mesothelial-Epithelial Transition (cMet) factor signaling, play an essential role in controlling synaptogenesis. Objectives: Because of the vital role of HGF and Met signaling in synaptogenesis and spatial learning function of the brain’s hippocampal region, we aimed to study the HGF and soluble cMet (s-cMet) serum levels in children with different stages of Autism Spectrum Disorders (ASD). Materials & Methods: A total of 189 ASD patients (mild; n=69, moderate; n=63 and severe; n=57) and 82 control were enrolled in this project. Blood samples were collected from ASD patients referred to Pediatric Neurology Clinic, 17 Shahrivar Hospital, Rasht City, Iran, and serum concentrations of s-cMet and HGF were measured by ELISA. The control children with no clinical characteristics of ASD attended routine blood tests. Results: HGF Mean±SD serum concentration in ASD patients was 239±52.02 pg/mL compared to controls which was 360.04±71.15 pg/mL (P=0.004). Also, the Mean±SD serum concentrations of HGF in mild, moderate, and severe ASD patients were 297.54±69.82, 232.81±56.41, and 189±33.25 ng/mL, respectively, compared to control, which was 360.18±57.40. Besides, the s-cMet Mean±SD serum concentrations in ASD and controls were 143.54±32.50 and 200.25±31.16 pg/mL, respectively (P=0.005). The Mean±SD serum concentrations of s-cMet in the mild, moderate, and severe ASD patients were 172.81±37.69, 129.81±45.55, and 85.18±22.95 ng/mL, respectively, as compared to the control, which was 214.54±34.17 ng/mL. Conclusion: Serum HGF and s-cMet concentration decreased in ASD patients corresponding to disease severity. Also, detecting serum HGF and s-cMet may help classify ASD.

scholarly journals Association of Hepatocyte Growth Factor Genetic Variation (S3735520) and Its Concentration in Autism Spectrum Disorders: A Case-control Study

2020 ◽  
Vol 6 (4) ◽  
pp. 197-204
Author(s):  
Masoumeh Khalili ◽  
◽  
Farhad Mashayekhi ◽  
Zivar Salehi ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Gene Polymorphism ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Autism Spectrum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Chi Square ◽  
Genotype Frequencies ◽  
Chi Square Test ◽  
Hepatocyte Growth

Background: Hepatocyte Growth Factor (HGF) was shown to play a key role in synaptogenesis, survival, maturation, and reconstruction of neuron cells and was shown to be implicated in Autism Spectrum Disorder (ASD). Objectives: Assessing the relationship between HGF (rs3735520) gene polymorphism and its circulating levels in ASD. Materials & Methods: A total of 140 ASD patients and 120 children healthy controls referred to Shahid Rajaei Hospital, Mazandaran, Iran from September 2017 to January 2019 were enrolled in the study. Genomic DNA was extracted from blood samples, HGF polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism and HGF serum concentration was measured by enzyme-linked immunosorbent assay. Statistical analysis was done by ANOVA and the Chi-square test, using χ² in MedCalc statistical software ver. 12.1.4. Results: Genotype frequencies of CC, CT, and TT in the ASD group were 25.71%, 52.86%, and 21.43%, and in controls were 26.67%, 68.33%, and 5%, respectively (P=0003) and C and T alleles frequencies in patients were 53% and 47% and in controls were 61% and 39%, respectively (P=0.046). Moreover, the Mean±SD serum HGF levels in the controls and ASD patients were 363.33±118.44 and 219.95±73.61 pg/mL, respectively (P=0.009). Furthermore, ASD patients carrying TT genotype had lower serum HGF levels than CT and TT carriers (CC, CT, and TT Mean±SD serum levels were 271.88±30.47, 217.77±33.59 and 156.33±22.72 pg/mL, respectively). Conclusion: There was a significant relationship between HGF gene polymorphism and its serum levels with ASD in an Iranian population. We also suggest that TT genotype may be associated with a decrease in HGF circulation levels in ASD.

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with severe Gastrointestinal Disease

2009 ◽  
Vol 4 ◽  
pp. BMI.S3656 ◽  
Author(s):  
A.J. Russo ◽  
A. Krigsman ◽  
B. Jepson ◽  
Andrew Wakefield
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Gastrointestinal Disease ◽  
Serum Levels ◽  
Autistic Children ◽  
Functional Connection ◽  
Disease Symptoms ◽  
Lymphoid Nodular Hyperplasia ◽  
Lymphoid Nodules ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in autistic children with severe gastrointestinal (GI) disease and to test the hypothesis that there is a relationship between GI pathology and HGF concentration. Subjects and Methods Serum from 29 autistic children with chronic digestive disease (symptoms for a minimum of 6–12 months), most with ileo-colonic lymphoid nodular hyperplasia (LNH—markedly enlarged lymphoid nodules) and inflammation of the colorectum, small bowel and/or stomach), and 31 controls (11 age matched autistic children with no GI disease, 11 age matched non autistic children without GI disease and 9 age matched non autistic children with GI disease) were tested for HGF using ELISAs. HGF concentration of autistic children with GI disease was compared to GI disease severity. Results Autistic children with GI disease had significantly lower serum levels of HGF compared to controls (autistic without GI disease; p = 0.0005, non autistic with no GI disease; p = 0.0001, and non autistic with GI disease; p = 0.001). Collectively, all autistic children had significantly lower HGF levels when compared to non autistic children (p < 0.0001). We did not find any relationship between severity of GI disease and HGF concentration in autistic children with GI disease. Discussion These results suggest an association between HGF serum levels and the presence of GI disease in autistic children and explain a potential functional connection between the Met gene and autism. The concentration of serum HGF may be a useful biomarker for autistic children, especially those with severe GI disease.

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor

1995 ◽  
Vol 268 (2) ◽  
pp. G380-G386 ◽  
Author(s):  
F. Roos ◽  
A. M. Ryan ◽  
S. M. Chamow ◽  
G. L. Bennett ◽  
R. H. Schwall
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Dextran Sulfate ◽  
Plasma Concentrations ◽  
Elevated Serum ◽  
Serum Levels ◽  
Serum Biochemistry ◽  
Scatter Factor ◽  
Liver Growth ◽  
Hepatocyte Growth

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent stimulator of DNA synthesis in a variety of epithelial cells, including hepatocytes, and has been implicated in liver regeneration. We show here that combining dextran sulfate with HGF/SF markedly increases the plasma concentrations of HGF/SF that are achieved during intraperitoneal infusion. Three days of administration of HGF/SF by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced. From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Tumor Biology ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Michael H.R. Eichbaum ◽  
Thomas M. de Rossi ◽  
Sepp Kaul ◽  
Thomas Bruckner ◽  
Andreas Schneeweiss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Liver Metastases ◽  
Serum Levels ◽  
Scatter Factor ◽  
Hepatocyte Growth

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Depression Correlates with Severity of Disease

2010 ◽  
Vol 5 ◽  
pp. BMI.S5183 ◽  
Author(s):  
A.J. Russo
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Disease Severity ◽  
Serum Levels ◽  
Lower Serum ◽  
Severity Of Disease ◽  
Clinically Depressed ◽  
Severity Of Depression ◽  
Predictive Strength ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in individuals with depression and to test the hypothesis that there is a relationship between severity of depression and HGF concentration. Subjects and methods Serum from 26 clinically depressed individuals and 19 controls were tested for serum HGF using ELISAs. Correlation was established between HGF concentration and disease severity. Results Depressed individuals had significantly lower serum levels of HGF compared to controls ( P < 0.0001). HGF concentration correlated with overall depressive behavior ( P = 0.03) and specifically depression ( P = 0.02), but not anxiety ( P = 0.36). Discussion These results suggest an association between HGF serum levels and clinically depressed individuals and demonstrate a correlation between severity of depression and HGF levels. Further studies of the predictive strength of HGF as a biomarker for depression may be warranted.

Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia

2009 ◽  
Vol 62 (2) ◽  
pp. 129-134 ◽  
Author(s):  
H. Hjorth-Hansen ◽  
C. Seidel ◽  
J. Lamvik ◽  
M. Börset ◽  
A. Sundan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Elevated Serum ◽  
Serum Concentrations ◽  
Myelocytic Leukaemia ◽  
Acute Myelocytic Leukaemia ◽  
Hepatocyte Growth

scholarly journals Hepatocyte growth factor and its receptor c-met in multiple myeloma

Blood ◽  
1996 ◽  
Vol 88 (10) ◽  
pp. 3998-4004 ◽  
Author(s):  
M Borset ◽  
H Hjorth-Hansen ◽  
C Seidel ◽  
A Sundan ◽  
A Waage
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Mononuclear Cells ◽  
Primary Cultures ◽  
Enzyme Linked Immunosorbent Assay ◽  
Myeloma Cells ◽  
The Mean ◽  
Hepatocyte Growth ◽  
Normal Controls

We have examined whether the hepatocyte growth factor (HGF)/c-met receptor-ligand pair is expressed in freshly isolated and highly purified myeloma cells and whether HGF can be found in the sera of myeloma patients. Myeloma cells were purified with an immunomagnetic method using the syndecan 1-specific antibody B-B4. HGF and c-met mRNA in these cells were examined by reverse transcriptase-polymerase chain reaction (RT-PCR). HGF and c-met proteins were detected by enzyme- linked immunosorbent assay (ELISA) and Western blot, respectively. Serum from 13 myeloma patients was obtained at diagnosis and the levels of HGF were determined by ELISA. HGF and c-met mRNA were expressed in all examined samples (n = 7). HGF was detected in the supernatants of 17 of 20 primary cultures of myeloma cells, whereas bone marrow mononuclear cells from normal controls did not produce detectable amounts of HGF (n = 3). The mean HGF level in serum of myeloma patients at diagnosis was more than fourfold higher than the mean level in normal controls. Possible implications of HGF/c-met expression for the pathophysiology of multiple myeloma are discussed.

scholarly journals Hepatocyte Growth Factor (HGF) Expression in High-Fat Diet Fed Rat Corpus Cavernosum. Preliminary results

2008 ◽  
Vol 14 (S3) ◽  
pp. 126-129 ◽  
Author(s):  
I. Tomada ◽  
N. Tomada ◽  
F. Marques ◽  
P. Vendeira ◽  
D. Neves
Keyword(s):  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Hepatocyte Growth Factor ◽  
Corpus Cavernosum ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Serum Levels ◽  
Epidemiological Studies ◽  
High Fat ◽  
Hepatocyte Growth

The main cause of erectile dysfunction (ED) is organic in nature, with vasculogenic etiology being predominant. Several epidemiological studies report the relationship between ED and several well-recognized cardiovascular risk factors, including atherosclerosis, diabetes, dyslipidemia, hypertension, as well as lifestyle factors, such as obesity and sedentarism. Recent findings also indicate that high-fat (HF) regular intake induces endothelial dysfunction and increases ED prevalence. Due to their interconnection, ED is considered equivalent to endothelial dysfunction, and it is nowadays seen as a predictive factor of atherosclerosis and cardiovascular disease (CVD). It is well established that the expression of some vascular growth factors is frequently diminished in corpus cavernosum (CC) of ED patients, and that its levels are particularly modified in metabolic syndrome (MetS). This syndrome combines more than three of the illnesses that prompt to vasculogenic ED: elevated blood pressure, high triglycerides, low high-density lipoprotein (HDL) cholesterol, elevated waist circumference, and insulin resistance. Hepatocyte Growth Factor (HGF) is a pleiotropic factor with potent mitogenic and angiogenic properties, previously employed in the treatment of ischaemic members. Interestingly, it was demonstrated that its serum levels were particularly increased in obesity and in MetS. HGF is expressed by several organs, but as far as we know, it has never been detected in CC. In this way, we present an immunohistochemical (IH) characterization of HGF expression in HF-diet fed rat CC.

Sign in / Sign up

Export Citation Format

Share Document